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Abstract  
 
There are increasing levels of concern relating to the rapidly evolving novel 
psychoactive substances/NPS and web markets’ scenarios. The paper aims at 
providing an overview of the clinical pharmacological issues related to some of 
the most popular NPS categories, e.g. stimulants and hallucinogens. NPS 
intake is typically associated with the imbalance of a complex range of 
neurotransmitter pathways/receptors, namely: dopamine; cannabinoid/CB1; 
and 5-HT2A. The intake is almost invariably undetectable with standard 
screening tests. Hence, it may frequently occur that the acute management of 
NPS misusers will need to focus on decreasing levels of both self/outward-
directed aggression and agitation. Benzodiazepines may be considered as first 
line treatment. Alternatively, propofol and/or antipsychotics can be 
administered. Focus will be as well on treatment of possible rhabdomyolysis 
and hyperthermia. Indeed, future studies should inform better tailored 
management/treatment strategies. 
 
Key words  
Novel psychoactive substances; Synthetic cannabimimetics; Synthetic 
cathinones; Hallucinogenic drugs; Phenethylamines; Psychiatric disturbances; 
Drug misuse. 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
ert
fo
rd
sh
ire
], 
[Jo
hn
 C
or
ke
ry
] a
t 0
2:4
0 1
8 M
arc
h 2
01
6 
  
Introduction 
Over the last decade, the drug scenario has shown significant levels of 
changes, with the emergence of a range of novel psychoactive substances 
(NPS). NPS are typically defined as new narcotic/psychotropic drugs which are 
not controlled by the United Nations’ 1961 Narcotic Drugs/1971 Psychotropic 
Substances Conventions, but which may pose a public health threat [1]. 
However, ‘novel’ typically refers to molecules that have recently become a 
reason of current/potential public health concern. At times, although 
misleading, the terms ‘legal highs’ or ‘research chemicals’ have been used as 
well to describe such substances, with the web playing a major role in shaping 
this unregulated market.[2]. Overall, there are increasing levels of concern 
about both the complex pharmacodynamics of these drugs and the appearance 
of acute/chronic medical and psychopathological manifestations associated 
with NPS intake.[1]  A concurrent use of a range of different NPS, and/or 
medications, is frequently being reported and this may be a reason of further 
concern.  
The present paper aims at providing an overview of the clinical 
pharmacological issues related to some of the most popular NPS categories, 
e.g. stimulants and hallucinogens (for a rapid overview, see Table 1).  
Methods 
We searched Medline/PubMed for studies using the terms “new psychoactive 
substances”, “novel psychoactive substances”, “legal highs”, “designer drugs”, 
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“research chemicals”, “smart drugs”, “emerging drugs of abuse”, “emerging 
drugs of misuse”, “stimulants”, “hallucinogenic drugs“, “psychedelics“, 
“synthetic cannabimimetics“, “synthetic cannabinoids“, and “spice“.  
The search was filtered by “English and human” and limited by publication 
dates to the last five years. In total, 4159 references were identified; of these, 
363 were considered potentially relevant. Some further 35 references were 
retrieved from specific websites identified by typing the index substance 
keywords on Google, with selection and analysis of fora posts/threads; and 
from national/international agencies’ reports. After a further thorough 
screening for eligibility, some 82 papers/documents had finally been 
considered here as suitable and consistent with the aims of the paper. 
 
Stimulants: synthetic cathinones; 4-4’-DMAR; methylphenidate-like NPS; 
amphetamine-type stimulants; aminoindanes; and cocaine analogues 
 
Synthetic cathinones 
The only cathinones under international control (United Nations Convention on 
Psychotropic Substances 1971) are amfepramone, cathine, cathinone, 
mephedrone, methcathinone and pyrovalerone. Although mephedrone (4-
methylmethcathinone) was originally synthesised in 1929, it first appeared on 
the drug scene in 2008,[3] and synthetic cathinones currently account for the 
second largest group of substances monitored by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA). Of the hundred or so 
cathinones notified to date to the EMCDDA, those which are a reason of 
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particular concern are: mephedrone; 4-MEC/4-Methylethcathinone; alpha-
PVP/α-pyrrolidinopentiophenone; flephedrone; MDPBP/3',4'-Methylenedioxy-α-
pyrrolidinobutyrophenone; MDPV/ Methylenedioxypyrovalerone; methedrone; 
methylone; naphyrone; pentedrone and pyrovalerone.  
Simmler and colleagues[4] have identified three categories of cathinones: (a) 
substrates for the dopamine (DAT), serotonin (SERT) and 
norepinephrine/noradrenaline (NET) transporters with MDMA-like profiles, e.g. 
mephedrone, methylone, butylone, ethylone, 4-MEC; (b) monoamine 
transporter substrates with DAT-selective profiles similar to amphetamine and 
methamphetamine, e.g. cathinone, methcathinone, flephedrone. Naphyrone 
and 1-naphyrone have very high potencies and some degree of selectivity for 
DAT; and (c) non-substrate transporter inhibitors, e.g. MDPV. 
Methcathinone (ephedrone) selectively generates a release of dopamine (DA) 
higher than that of serotonin (5-HT). MDPV is a DA selective uptake inhibitor, 
but selectively blocks the uptake of DA more than 5-HT, and presents with a 
high abuse potential.[5] MDPV inhibits monoamine uptake at the DA, 5-HT and 
norepinephrine (NET) transporters, similarly to cocaine.[6,7] The behavioural 
effects of mephedrone and MDPV are similar to methamphetamine and cocaine 
respectively, whilst methylone’s are closer to MDMA.[8] MDPV, mephedrone, 
methcathinone, and naphyrone are potent NET inhibitors.[9]  
Synthetic cathinones are typically sold as pills, capsules and powders. They are 
usually snorted/sniffed (insufflated), taken orally by ‘bombing’ (swallowing the 
powder wrapped in a cigarette paper), mixed in a drink, or through 
intravenous injecting. 
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Synthetic cathinones are often used by consumers for various reasons, 
including: hallucinogenic experiences, euphoria, mood enhancement, 
openness, empathy, mental clarity, stimulation, increased energy, and 
increased libido.[10] Mephedrone possesses a re-dosing risk due to half-life 
being as short as 1h.[11] By contrast, MDPV is thought to have a half-life of 3-
5 h. Several different cathinones are often used together, and this could cause 
synergistic effects, e.g. as with MDPV and mephedrone. [9]  
The most common cathinones’ adverse reactions are restlessness and anxiety,  
ranging from mild agitation to severe psychosis. Furthermore, tachycardia, 
hypertension, abdominal pain, chills, flushing, sweating, hyperthermia, renal 
failure, rhabdomyolysis, and seizures can also be observed.[1,12-14] Paranoid 
ideation and mood disturbances have been observed in chronic users of both 
natural and synthetic cathinones.[13-16] Many synthetic cathinones users 
report tolerance, dependence and withdrawal symptoms.[17]  
Injecting use of synthetic cathinones has emerged among specific sub-
populations’ segments of at least 10 EU countries.[18] In some areas in 
Europe (e.g. eastern Europe), such injectors account for more than half of all 
drug injectors, with problem drug users now switching from heroin. The intake 
of cathinones can occur with high frequency levels, e.g. up to 10-20 times 
injections per day. MDPV, mephedrone, and 4-MEC are all reported to be 
injected. A more recent development is the injecting of α-PVP in Ireland.[19] 
Within the ‘Chemsex’ (e.g. the use of misusing drugs to increse levels of 
libido/sexual performances) context, drugs including synthetic 
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cathinones/mephedrone are described as having a significant influence on the 
risk-taking behaviour of ‘men who have sex with men’/MSM population.[20] 
Some 83 deaths involving synthetic cathinones had been registered by the end 
of 2014 in England and Wales.[21] Although most fatalities involved 
mephedrone, increasing numbers of α-PVP and pentedrone deaths are being 
reported in the EU. Cathinones are typically involved in hangings or other 
mechanical suicides.[13,14]  
 
4,4’-dimethylaminorex (4,4’-DMAR) 
4,4’-dimethylaminorex (4,4’-DMAR, “Serotoni”), a derivative of aminorex, is a 
powerful dopamine/noradrenaline releaser whilst inhibiting the SERT as well. It 
may be snorted, or ingested, to achieve levels of both elation and increased 
alertness. The relating anxiety/agitation may last for a number of hours, with 
the risk of increase in body temperature and cardiorespiratory problems. [22]   
“Serotoni” has recently been associated with some 35 fatalities in Europe.[1] 
 
Methylphenidate-like NPS 
Ethylphenidate (EPH; sold under a range of brandnames such as ‘Burst’, ‘El 
Blanco’, ’Gogaine’) is the ethyl-homologue of methylphenidate (MPH). It 
appeared in the UK market in 2011 and has now become one of the most 
popular NPS. Both EPH and MPH are stimulant drugs, being potent inhibitors of 
both DA and noradrenaline (NE) reuptake, although EPH is almost 5 times less 
potent against NE than DA, and MPH is less selective.[23] Other MPH-derived 
compounds have recently appeared on the market, such as 3,4-
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dichloromethylphenidate (3,4-DCMP); methylnaphthidate (HDMP-28); 
propylphenidate; and isopropylphenidate. 3,4-DCMP is claimed to be more 
potent than MPH, with a slower onset of action and longer duration.[23]  
HDMP-28 acts as a triple receptor re-reuptake inhibitor (DA, NE, and 5-HT) in 
a manner similar to cocaine;  it is also claimed to have several times the 
potency of MPH, but with a shorter duration of action.[23]   
EPH can also be found as an extra ingredient in psychoactive compounds’ 
mixtures, together with methiopropamine, ephedrine, phenylethylamine, and 
remaining stimulants.[23,24] EPH intake can occur orally, intranasally, 
rectally, or through intramuscular/intravenous injection. Commonly reported 
dosages are 10-100 mg for oral or intranasal administration, and 5-50 mg for 
injection.[25] The mean onset time for the EPH ‘high’ is around 15 minutes for 
intranasal, and 25 minutes for oral administration; the mean duration of the 
effects  is 120 minutes for all routes of administration. It has been suggested 
that, at low doses, EPH encourages increased levels of motor/mental 
productivity, whilst at higher dosages this may result in a general lack of motor 
control.[26] EPH can be found in powder; crystalline; and tablet form. 
Common desidered effects reported by users include euphoria, 
stimulation/increased arousal, improved concentration, sociability, and sexual 
drive. Conversely, adverse effects reported include muscle tension, 
palpitations, sweating, appetite loss, anxiety/restlessness, insomnia, paranoia, 
and auditory/visual hallucinations.[24] EPH intake has been associated with 
bizarre/erratic and violent behaviour, suicidality, psychosis, and clinical 
worsening of paranoid schizophrenia.[23] Tolerance to EPH has been 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
ert
fo
rd
sh
ire
], 
[Jo
hn
 C
or
ke
ry
] a
t 0
2:4
0 1
8 M
arc
h 2
01
6 
described. Many users report a concurrent intake of a range of substances, and 
in particular  of sedative drugs such as alcohol, benzodiazepines and/or opiates 
used as ‘downers’, together with EPH. A ‘crash’-like phase after the end of an 
EPH binge session, with a period of mood lowering and fatigue, has been 
described.[27] As it might be expected from a short half-life stimulant which 
boosts DA levels, users report a strong urge/compulsion to re-dose.[23,27,28] 
A significant outbreak of severe soft-tissue infections among drug users who 
report injecting EPH repeatedly has been recently identified.[23] Twenty-eight 
fatalities associated with analytically confimed EPH ingestion, mostly in 
combinationoth other drugs, have been described. 
 
Amphetamine-type stimulants/novel stimulants  
Amphetamine-type substances (ATS) include: PMA (4-methoxyamphetamine); 
PMMA (4-methoxymeth-amphetamine); 4-MTA (4-
methylthioamphetamine/“flatliners”); DMA (2,5-dimethoxyamphetamine); 
diclofensine; methiopropamine/MPA; etc.[1,29]  
PMA and PMMA (aka ‘red Mitsubishi’/’pink ecstasy’/’Mitsubishi turbo’/’Dr. 
Death’) are similar to MDMA, although these molecules are already extremely 
active at lower doses. They may determine a fatal rise in body temperature, 
euphoria, a sense of full energy, an amplification of sounds/colours and 
feelings of love/sociability. An increasing number of fatalities have been 
described following their consumption.[30] 
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Diclofensine is a stimulant that acts as a DA/NE/5-HT reuptake inhibitor.[31] It 
was originally developed as an antidepressant, but eventually abandoned due 
to possible concerns about its potential for abuse.[32] 
Methiopropamine (MPA; ‘Blow’) was firstly synthetized in 1942 but advertised 
on the Internet as a ‘research chemical’ in late 2010.[33-36] It acts as a 
selective NE/DA reuptake inhibitor.[37] It may be ingested, snorted, or 
smoked.  At low doses, it is a stimulant associated with mild euphoria, 
alertness, sexual arousal, loss of appetite, tachycardia, anxiety, etc. Adverse 
effects include a significant hangover after extended use with nausea, 
headache, dizziness, lack of energy, skin irritation and difficulty urinating.[1] 
 
Aminoindanes 
The UNODC [38] reports that up May 2015 the most commonly reported 
aminoindanes were 5,6-methylenedioxy-2-aminoindane (MDAI; ‘MDAI gold’); 
5-iodo-2-aminoindane (5-IAI); and 2-aminoindane (2-AI; Blurberrys’, ‘Groove-
e’, ‘Pink Champagne’). Other aminoindanes available as NPS include: N-
methyl-2-aminoindane (N-methyl-2AI; NM-2AI); 1-aminoindane; and ETAI (N-
ethyl-5-trifluoromethyl-2-aminoindane). Although some of these molecules are 
controlled in specific countries, none of them are subject to control under the 
UN international Drug Conventions. The aminoindanes’ potential to affect 
serotonin release and re-uptake [39] is likely to be associated with the ability 
to engender entactogenic and empathogenic effects akin to those of 
MDMA.[40] 
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Most aminoindanes are available from a range of sources, including the web, 
as tablets, powder, and capsules/tablets which can be either ingested or 
snorted.  
Aminoindanes are used by consumers in search of a range of psychaoctive 
effects, including: hallucinogenic experiences, euphoria, mood enhancement, 
openness, empathy, mental clarity, stimulation, increased energy, and 
increased libido.[41] 
Aminoindanes are reported to cause eye and skin irritation, as well as 
gastrointestinal disturbances with nausea, vomiting/diarrhoea, and respiratory 
tract concerns. Three deaths associated with MDAI use, either alone or in 
combination,  were identified in the UK during 2011-2012, all involving 
symptoms consistent with serotonin syndrome.[42]  
 
Synthetic cocaine analogues 
Dimethocaine and 4-fluorotropacocaine (pFBT), typically found as white 
powder, act as DA reuptake inhibitors, resulting in mild stimulant effects. 
Similar to cocaine, both substances are being insufflated since following 
ingestion they would be hydrolysed by the digestive system esterases. 
Dimethocaine users report a short-lasting rush, together with levels of 
increased attention/concentration, talkativeness, and the desire to re-dose. 
Adverse/unwanted effects include peripheral vasoconstriction, tachycardia, 
diaphoresis, muscle twitching, nausea, and vomiting.[41] pFBT is anecdotally 
reported to cause hypertension, tachycardia, anxiety and temporary 
psychosis.[41] Further cocaine analogues include RTI-111 (e.g. a potent 
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stimulant acting as an inhibitor of 5-HT, DA and NE reuptake[43]); RTI-121 
and RTI-126. RTI-121  is a potent/long-lasting stimulant acting as a selective 
DA reuptake inhibitor.[44] RTI-126,[45] on the other hand, may present with 
a potency which is 5-fold higher than that of cocaine. When snorted, these 
compounds are associated with alertness, euphoria, talkativeness, insomnia, 
prolonged residual tension/anxiety, and crash-like symptoms.[1] 
 
Hallucinogens: synthetic cannabimimetics; psychedelic phenetylamines; and 
tryptamines  
 
Synthetic cannabimimetics 
Synthetic cannabimimetics (SC; ‘Spice’) were first detected in Europe towards 
the end of 2008 and, at the time of writing, constitute the largest group (about 
30%)  of NPS monitored by the EMCDDA. SC belong to a range of chemically 
different families of compounds. Some are cannabinoid receptors’ agonists 
whilst others are compounds targeting enzymes involved in the metabolism 
and transportation of endocannabinoids.[46] Many SC contained in Spice drugs 
are full-agonists, possess large levels of receptors’ affinity, and hence elicit 
maximal activity at cannabinoid receptors.[47] Conversely, THC effects in 
cannabis are modulated/dampened by the presence of other natural 
compounds such as terpenoids, cannabidiol and tetrahydrocannabivarin,[46] 
but no such ‘modulating’ compounds are generally detected in Spice 
products.[48] Several SC have been found to interact with a range of 
remaining receptors, including: 5-HT, nicotinic acetylcholine, glycine, and/or 
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ionotropic glutamate (NMDA), and it is possible that SC produce their complex 
effects through their actions at non-cannabinoid receptors as well.[48] A 
number of SC compounds incorporate indole-derived moieties active on 5-HT 
receptors, either as components of the structure or as substituents. It has 
been suggested that, at high doses, SC compounds may also possess some 
monoamine oxidase, and 5-HT reuptake, inhibitory properties.[49] These 
complex pharmacodynamic elements may further increase the risk of serotonin 
syndrome occurrence in SC misusers.[10,46] Furtherly, it has been suggested 
that the chronic activation of CB-2 receptors results in the upregulation of 5-
HT2A receptors in the prefrontal cortex of mice.[50] Modification in 5- HT2A 
receptors’ neurotransmission has been associated with 
hallucinations/delusions/psychosis.[51] 
‘Spice’ preparations are composed by both a dried plant base, to mimic the 
‘grass effect’ of female cannabis dried inflorescences, and a mixture of SC 
which are sprayed on it. SC dispersed in the grass preparation look like 
hashish, with capsules and e-liquid formulations being available as well. SC 
have also been found in tablets and sprayed on herbal cannabis. SC can be 
found on the web, from ‘head–shops’, gas stations, and from an ever 
expanding range of other outlets.[52] 
Their intake can occur through inhalation from a joint/bhong/pipe or using a 
vaporizer. Other ways of intake include: insufflation, oral ingestion, rectal 
administration and injection.[1] Misusers are often young males, choosing 
Spice instead of cannabis for its low cost; favourable legal status;[41] easy 
availability; mis-perception that SC are natural, and not synthetic, molecules; 
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and undetectability in routine urine screening tests.[53,54] The non-
detectability of SC make also Spice very attractive for sub-populations 
undergoing regular drug tests.[10]  
Spice products are almost always laced with multiple SC in a single 
preparation.[1] Hence, there is a potential for drug–drug interactions between 
multiple SC in a single product, and this may contribute to the abuse-related 
and synergistic effects of these compounds. Some SC metabolites, 
furthermore, retain levels of both affinity and activity for CB-1 receptors, 
hence contributing to the toxicity of the products.[55] The recent trend of SC 
fluorination may increase the compounds’ lipophilicity, hence promoting the 
absorption through biological membranes/blood brain barrier, possibly 
enhancing the SC overall toxicity.[55] 
The total lack of product quality control may lead to significant differences in 
concentration (‘hot-spots’) of SC present in herbal incenses or e-
liquids.[46,55] In comparison with cannabis, use of SC may be characterized 
by quicker ‘kick off’ effects; significantly shorter duration of action; larger 
levels of hangover effects; and more intense visual hallucinations, paranoid 
feelings, and behavioural dyscontrol.[46,56] The acute SC intoxication is 
characterized by a short-lived clinical picture with reported signs/symptoms of 
elevated heart rate/blood pressure levels; visual/auditory hallucinations; 
mydriasis; agitation/anxiety; hyperglycaemia; dyspnoea/tachypnoea; and 
nausea/vomiting.[1] 
Other psychiatric and neurological effects include: suicidal ideation/self-
injurious behaviour; aggressive behaviour; panic attacks; cognitive 
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impairment; thought disorganisation; psychosis; agitated/excited delirium; 
nystagmus; seizures; hyperemesis; encephalopathy; acute kidney injury; 
rhabdomyolysis; hyperthermia; serotonin syndrome; toxic hepatitis/liver 
failure; coma; severe dysrhythmias/cardiotoxic effects; and stroke.[1,56]  
Long-term SC misuse may also be associated with tolerance, dependence, and 
a severe prolonged withdrawal syndrome, characterized by drug craving, 
tachycardia, tremor, profuse sweating and diarrhoea, nightmares/insomnia, 
headache, anxiety/irritability, mood swings, feelings of emptiness/depressive 
symptoms, and somatic complaints.[1] SC intake has been associated with a 
range of psychotomimetic disturbances (e.g. paranoia, delusions, 
hallucinations), the occurrence of florid/acute transient psychosis, 
relapse/worsening of a pre-existing psychosis, persistent psychotic 
disorder/‘Spiceophrenia’;[56] and relapse of a pre-existing bipolar 
disorder.[57] A number of deaths have been related to SC ingestion, either on 
their own or in combination, in analytically confirmed reports.[1] Very recently, 
a phase I clinical trial for the development of a painkiller drug akin the ones 
found in Spice was abruptly terminated due to severe neurological adverse 
effects and one death among a number of human volunteers.[58]  
 
Psychedelic phenetylamines 
Phenethylamines include a wide range of natural or synthetic substances which 
own psychostimulant, entactogenic and hallucinogenic effects. Mescaline, 
isolated from peyote cactus (Lophophora williamsii) and traditionally chewed 
by Indians in Mexico as a religious sacrament, represents the prototype 
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psychoactive phenethylamine compound. A variety of methoxylated 
amphetamine compounds are derived by mescaline, and include: TMA (3,4,5-
trimethoxyamphetamine); DOM (3-methoxy-4,5-
methylenedioxyamphetamine); DOET (2,4,4-trimethoxyamphetamine); DOI 
(4-iodo-2,5-dimethoxyamphetamine); DOC (4-chloro-2,5-
dimethoxyamphetamine), etc.[59] Alongside these substances, the group of 
phenethylamines also include a total of 179 ‘classical’ phenethylamines, such 
as: MDMA (3,4-methylenedioxymethamphetamine)-like drugs (e.g. MDA [3,4-
methylenedioxy-amphetamine]; MDEA [3,4-methylenedioxyethamphetamine]; 
MBDB [N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine]; and the latest 
generation phenethylamine derivatives: e.g. ‘Bromodragonfly’ (1-(8-
bromobenzo[1,2-b; 4,5-b′]difuran-4-yl)-2-aminopropane); NBOMe derivatives; 
indanes; benzofurans; and the class of 2C- molecules such as 2,5-dimethoxy-
4-bromophenethylamine (2C-B), 2,5-dimethoxy-4-iodophenethylamine (2C-I); 
and 2,5-dimethoxy-4-ethylphenethylamine (2C-E).[1]  
Bromo-Dragonfly (aka ‘DOB-Dragonfly’/’3C-Bromo-Dragonfly’ [60]) displays a 
high affinity for 5-HT2A, 5-HT2B, and 5-HT2C receptors.[61]  Its effects are 
associated with long-standing hallucinations, mood elevation, paranoid 
ideation, confusion, anxiety and flashbacks. In addition, both a number of 
related acute intoxications with convulsions, respiratory problems, liver and 
kidney failure, severe vasoconstriction, and fatalities have been described.[60]   
The 2C-series compounds, including: 2,5-dimethoxy-4-bromophenethylamine 
(2C-B; ‘Nexus’), but also 2,5-dimethoxy-4-methylphenethylamine (2C-D), 2,5-
dimethoxy-4-ethylphenethylamine (2C-E), 2,5-Dimethoxy-4-
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nitrophenethylamine (2C-N), 2,5-Dimethoxyphenethylamine (2C-H), N-ethyl-
2C-B, etc.[29] act primarily at the 5-HT2A receptors, also displaying low-affinity 
binding to D2 receptors and a low inhibitory activity to monoamine 
transporters (for a thorough review, see Rickli, and colleagues[62]). Adverse 
effects include headache, dysphoria, hallucinations, mydriasis, seizures, severe 
agitation, and apnoea. Several related deaths have been reported as well.[1] 
Recently, several highly active N-benzyl substituted phenethylamines 
(NBOMEs) have entered the NPS market and include: 25B-NBOMe ((2-(4-
bromo-1,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine)); 25C-NBOMe 
((2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine) aka ‘N-Bomb’/‘Pandora’); and 25I-NBOMe 
((4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine) aka ‘N-
bomb’).[29,63,64] In vitro receptor studies have demonstrated that NBOMe 
compounds act as potent full agonists at the 5-HT2A and 5-HT2C receptors.[65] 
In addition, 25I-NBOMe and 25C-NBOMe are pharmacologically active at very 
low, sub-milligram, doses.[29] They also display high binding affinity to 
adrenergic α1A and α2A, as well as histamine H1, receptors. They show as well 
low-affinity binding levels to D2 and D3 receptors.[62] Their higher 5-HT2A 
receptor affinity, compared to the 2C- derivatives, explain the frequent 
associated reports of hallucinations and delusions. NBOMe-containing products 
are usually available as tablets, capsules, powder, liquid, spray, and blotters. 
They are usually taken sublingually/orally or via nasal insufflation.[29] Some 
of them are sold as LSD replacement.[29,63] Depending on the route of 
administration, their effects may last 3-10 hours. Psychotropic effects 
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commonly reported include euphoria, increased sociability, 
visual/auditory/olfactory/tactile perceptual disturbances, empathy, 
depersonalization, dissociation and derealization. Their adverse effects may 
include nausea, vomiting, headache, panic/severe agitation, aggressiveness, 
seizures, insomnia, muscle rigidity/rhabdomyolysis with renal failure, tremors 
and cardiopulmonary arrest.[29,63] Several fatalities have been reported 
following the intake of NBOMe compounds.[66]  
Benzofurans, which are phenethylamines structurally related to MDMA and 
MDA (3,4-methylenedioxyamphetamine), include several compounds, e.g.: 6-
APB (6-(2-aminopropyl) benzofuran; aka ‘BenzoFury’); 5-APB (s (5-(2-
aminopropyl)benzofuran); 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
aka ‘4-Desoxy-MDA’); 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran; aka 
‘3-Desoxy-MDA’); etc.[29] They are typically ingested, since nasal insufflation 
may be painful. Their intake may be associated with stimulant, entactogenic 
and hallucinogenic effects. Adverse effects may include: dry mouth, nausea, 
jaw/teeth clenching, insomnia, diarrhoea, light hypersensitivity, hot flushes, 
headache, drowsiness, panic attacks/anxiety, depression, severe paranoia and 
psychosis. An unpleasant ‘come-down’, lasting several days, has been 
reported.[67] Several deaths related to 5- and 6-APB have been identified.[68]  
 
Tryptamines 
Tryptamines have been classified in two groups: a) ‘simple tryptamines’, 
structurally derived from tryptamine; and b) ‘ergolines’, structurally related to 
the semi-synthetic lysergic acid diethylamide/LSD.[69]  
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Simple tryptamines 
Apart from N,N-dimethyltryptamine (DMT); other tryptamine derivatives 
include: 5-MeO-DMT/5-methoxy-n,n-dimethyltryptamine, found in some 
Delosperma species; psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine); 
and psilocin (4-hydroxy-N,N-dimethyltryptamine), which are identified in 
hallucinogenic fungi (aka ‘magic shrooms’ or ‘mushies’); bufotenin (5-hydroxy-
N,N-dimethyltryptamine/5-OH-DMT); and 5-hydroxy-indolethylamines, 
common constituents of venoms of the genre Hyla, Leptodactylus, Rana and 
Bufo alvarius.[70] Tryptamines psychoactive effects are due to their agonism 
at 5-HT1A, 5-HT2A and 5-HT2C receptors.[71] Other receptors implicated in the 
tryptamine pharmacodynamics include vesicular monoamine transporter 2 
(VMAT2), σ-1, serotonin transporter (SERT) and traceamine-associated (TAR) 
receptors.[71] 
DMT (aka ‘Dimitri’/’businessman’s trip’) has been found in the leaves of 
Psychotria viridis, which are traditionally combined by the indigenous 
Amazonian tribes with Banisteriopsis caapi, source of the monoamine oxidase 
inhibitors (MAOi) β-carboline alkaloids harmine, harmaline and 
tetrahydroharmine,  to produce Ayahuasca. DMT has been also found in other 
plant sources, e.g.  Phalaris arundinacea and Mimosa hostilis.[72] DMT 
produces strong hallucinogenic LSD-like effects, powerful entheogenic 
experiences/intense visual hallucinations, and euphoria. Since DMT is inactive 
after oral administration unless combined with MAOis, it is usually injected, 
snorted, or smoked. If smoked, its effects last for a short period of time (5-30 
minutes).[73]  
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Psilocin hallucinogenic effects occur within the first 2 hours after oral intake 
and last up to 4-8 hours.[74] Psilocin is a partial 5-HT2A agonist, with little 
dopaminergic or noradrenergic activity.[75,76]  
Bufotenin (aka ‘5-OH-DMT’) is found in the skin of various species of the toad 
Bufo genus; in mushrooms such as Amanita; and in plants such as 
Anadenanthera and Piptoderma peregrina.[77] It acts on 5-HT2A 
receptors.[78]  
Alongside these naturally occurring tryptamines, a rapidly increasing number 
of tryptamine derivatives, such as:  5-Meo-DALT (N-diallyl-5-methoxy-
tryptamine); AMT (α-methyltryptamine); AET (α-ethyltryptamine); 5-Meo-AMT 
(5-methoxy-α-methyltryptamine);  4-HO-DALT (N,N-diallyl-4-
hydroxytryptamine); 5-MeO-DIPT (5-methoxy-diisopropyl-tryptamine; aka 
‘foxy’ or ‘foxy methoxy’); DET (N,N-diethyltryptamine); and 5-IT (5-(2-
aminopropyl)indole); have recently entered the market. These tryptamine 
derivatives are usually available as capsules, tablets, powder or liquid 
formulations and may be ingested, snorted,  smoked or injected.[41] The main 
clinical effects are visual hallucinations, alterations in sensory perception, 
intensification of colours, distortion of body image, depersonalization, marked 
mood lability, euphoria, relaxation, entactogenic properties, and anxiety. 
Adverse effects include agitation, tachyarrhythmias, hyperpyrexia, 
serotoninergic neurotoxicity and death.[41] 
AMT (aka ‘Day Tripper’/IT-290) and AET (aka ‘Love Pearls’/ET) possess central 
stimulant and hallucinogenic properties. AMT desired effects, peaking in 3-4 
hours and lasting up to 12-24 hours, include: euphoria, distortion of 
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colour/shapes and visual hallucinations. AET is a reversible MAOi and 5-HT/DA 
releasing molecule. AET onset of action occurs within 30-90 minute; its 
adverse effects may include: facial flushing, headache, gastrointestinal 
disorders, irritability, insomnia and, at times, hyperthermia and agitated 
delirium. Although it may be made available as an LSD alternative, due to its 
amphetamine-like structure 5-MeO-AMT presents with a range of 
sympathomimetic effects. It owns a strong binding activity at 5-HT1A and 5-
HT2A receptors whilst inhibiting as well the monoamines’ reuptake.[79] 5-MeO-
DIPT (aka ‘foxy/‘foxy methoxy’/5MEO), structurally related to DMT and 
bufotenin, is an agonist at 5-HT2A, 5-HT1A, and 5-HT2C receptors. Its adverse 
effects include nausea, vomiting, mydriasis, auditory and visual hallucinations, 
formication, tachycardia, hypertension, echolalia, paranoia, 
restlessness/agitation and muscle tension.[36] DET significantly inhibits 
monoamine oxidase. It produces hallucinogenic effects similar to DMT or 
mescaline. Adverse effects include anxiety, tremors, nausea/vomiting, 
mydriasis, disinhibition, visual distortions and increased blood pressure.    
Ergolines 
LSA has been found in the seeds of Argyreia nervosa and Ipomoea violacea. It 
is traditionally used during shamanic and ceremonial practices. LSD appears as 
a crystalline powder soluble in water which is made available as sugar cubes or 
small squares of papers or stamps (‘microdots’) which are typically ingested. 
Its effects are rapid and include headache, raised pulse rate, dilated pupils, 
nausea, blood pressure alterations and sometimes an increase in body 
temperature. Its effects vary according to both the subject expectation/mood 
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and the setting, including idiosyncratic perceptual disturbances such as: 
stationary objects appearing to move and changing shape; synesthesia; 
distortions of body image and perception of time etc. Tolerance, dependence 
and withdrawal experiences have been described by users. Adverse effects 
may include ‘bad trips’, i.e. an unpleasant, often terrifying, post-intake drug 
experience. Spontaneous recurrence of the drug-induced experience (i.e. 
flashbacks) is fairly common after LSD use. Some novel LSD derivatives have 
recently reached the market, such as: LSZ (lysergic acid 2,4-
dimethylazetidide); 1-P-LSD (1-propionyl-d-lysergic acid diethylamide 
hemitartrate) ; ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide); PRO-LAD 
(6-propyl- 6-nor-lysergic acid diethylamide), and AL-LAD (6-allyl-6-nor-
lysergic acid diethylamide). They produce effects resembling those of LSD, 
having similar pharmacological action at 5-HT2A-receptors, but  possessing 
different potencies, kick-off effects and duration.[29] 
 
Expert Commentary; NPS use as a clinical challenge for emergency physicians  
The constantly and rapidly evolving NPS drug scenario represents a challenge 
for medicine, and especially so for both emergency physicians and mental 
health professionals. Indeed, NPS intake is typically associated with the 
imbalance of a range of neurotransmitter pathways/receptors. Hence, this may 
be followed by a range of psychopathological disturbances [1], whose 
occurrence has been related to : a) increased central dopamine levels, 
associated with the intake of most of these substances, including novel 
psychedelic phenethylamines, stimulants, synthetic cathinones and 4,4’-DMAR; 
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b) cannabinoid CB1 receptor activation, achieved with synthetic 
cannabimimetics; and c) intense 5-HT2A receptor activation, reported with both 
NBOMe compounds and latest tryptamine derivatives.  
Due to the NPS complex pharmacodynamics here described, levels of debate 
are currently occurring in formal clinical fora to identify a range of proper, 
NPS-focused, management/treatment strategies. In fact, NPS consumers may 
present overnight to accident and emergency departments without disclosing 
their drug intake whilst it is also likely that the standard drug tests will show 
negative results. It is problematic to draw a detailed and universal 
management plan to cope with the behavioural and psychopathological 
disturbances related to the intake of the virtually few hundreds of substances 
currently available.[80] However, according to Velez and Benitez,[81] the 
initial management of these patients should focus on decreasing levels of both 
self/outward-directed aggression and agitation. Verbal de-escalation can 
always be considered with more cooperative patients. However, given the 
complex, and at times unknown, pharmacology of the substances possibly 
ingested by the client, benzodiazepines may be considered as agents of 
choice.[1] Initially, due to lack of patient cooperation, the intravenous/IV 
access may be problematic. In those cases, Velez and Benitez have suggested 
to use either intramuscular/IM or intranasal midazolam (5-10 mg IM/intranasal 
or 2.5-5mg IV), because of its fast absorption/onset of action; or lorazepam 
(4-8 mg IM; 2-4 mg IV).[81] Diazepam should only be used IV, as it presents 
with erratic IM absorption.[81]  Benzodiazepines, however, need frequent re-
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dosing/high dosages to achieve adequate sedative effect, and this may be a 
problem if clients have co-ingested alcohol.  
Where patients cannot be controlled with benzodiazepines alone, propofol 
and/or antipsychotics (especially when paranoia and psychosis are being 
identified) may be considered, although this may further contribute to the 
acute toxicity effects of the abused substances. Both haloperidol and 
droperidol (5-10 mg IM or IV) have been suggested as reasonable options.[81] 
Aripiprazole, quetiapine, risperidone, and olanzapine can also be used, 
although the levels of evidence regarding their use for the undifferentiated 
agitation patient is limited.[81] 
Treatment of hyperthermia needs to be aggressively planned, and this typically 
involves cooling measures and, once an IV line is available, focus should be on 
control of rhabdomyolysis with intravenous fluid administration.[1; 81] The 
serotonin syndrome is managed using benzodiazepines and cyproheptadine.[1] 
Inpatient admission, possibly to intensive care units, may at times be needed. 
 
Five-year view  
Indeed, future studies will provide better levels of NPS clinical and basic 
pharmacology-related knowledge, so that better tailored 
management/treatment guidelines can be made available.  
Health professionals’ education involving knowledge on NPS health harms, 
potential interventions, and referral pathways is lacking. Future NPS-related 
tutoring activities will allow clinicians to promote health prevention and 
education activities, which in turn would reduce the negative social impact of 
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NPS misuse; unnecessary hospital admissions; and avoidable fatalities. [82] 
Future approaches will consider as well the role of web-based preventative 
strategies in targeting youngsters/vulnerable individuals at risk of approaching 
the NPS market. 
Although current general population surveys suggest relatively low levels of 
NPS use, at least if compared with well-known scheduled substances such as 
THC, cocaine and heroin, this may change. The online market of novel 
psychoactive substances is unfortunately developing far more rapidly than 
academic research. Hence, it is more than likely that over the next 5 years or 
so the number of NPS will continue to rise. Similarly to Poland and Ireland, 
however, a brand new legislation focussing on NPS is expected to come into 
effect in the UK in April 2016. As a result of this, it is speculated that most of 
the so called ‘legal highs’/’research chemicals’, now considered as technically 
‘legal’, will be outlawed. Since at present a sizeable proportion of the NPS are 
made available to customers through the most popular ‘open web’ search 
engines, one could hypothesize that over the next few years the NPS market 
will gradually expand and/or move to the ‘deep web’, and especially to its most 
hidden portion, e.g. the ‘DarkNet’.[2] It is hence here speculated that most 
transactions of NPS will occur in the future with the help of both ‘ad hoc’, 
deep-web tailored,  browsers and a range of ‘crypto currencies’, some of which 
are already available for use. Current research activities, coordinated from our 
group, are already focussing on these possible future scenarios.  
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Key issues 
 
• Over the last decade, the drug scenario has shown significant levels of 
changes, with the emergence of a range of novel psychoactive substances 
(NPS). The web may play a major role in shaping this unregulated market  
 
• An overview of the clinical pharmacological issues related to some of the 
most popular NPS categories, e.g. stimulants (e.g.  synthetic cathinones; 4-4-
DMAR; methylphenidate-like NPS; amphetamine-type stimulants; 
aminoindanes; and cocaine analogues); and hallucinogens (synthetic 
cannabimimetics; psychedelic phenethylamines and tryptamines) is here 
provided (see Table 1). 
 
• NPS intake is typically associated with the imbalance of a range of 
neurotransmitter pathways/receptors, which in turn may be followed by the 
occurrence of a range of psychopathological disturbances, due to: a) increased 
central dopamine levels, associated with the intake of most of these 
substances, including novel psychedelic phenethylamines, stimulants, synthetic 
cathinones and 4,4’-DMAR; b) cannabinoid CB1 receptor activation, achieved 
with synthetic cannabimimetics; and c) intense 5-HT2A receptor activation, 
reported with both NBOMe compounds and latest tryptamine derivatives.   
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• NPS intake usually fails to be identified with standard drug screening 
tests. Advanced tests can be performed, but they are not generally available in 
the acute setting and are used mainly for forensic investigations. 
 
• The initial management of these patients should focus on decreasing 
levels of both self-/outward-directed aggression and agitation. Due to the 
complex, and at times unknown, pharmacology of the NPS/other psychoactives 
ingested by the client, benzodiazepines may be considered as agents of choice  
 
• It is more than likely that over the next 5 years or so the number of NPS 
will continue to rise. A brand new legislation focussing on NPS is expected to 
come into effect in in the UK April 2016. It is speculated that over the next few 
years the NPS market will gradually expand and/or move to the ‘deep web’, 
and especially to its most hidden portion, e.g. the ‘DarkNet’.  
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 Table 1: Stimulant and hallucinogenic novel psychoactive substances (NPS); chemical structure; pharmacodynamics; 
gergal/colloquial names; psychoactive effects and medical/psychopathological consequences 
 
Stimulant NPS 
Class Structure Action Gergal/colloqui
al names 
Psychoactive effects and 
medical/psychopathological consequences  
Synthetic 
cathinones  
 
Analogues of beta-
ketoamphetamine 
cathinone  
 
Substrates for DAT, SERT and 
NET  
‘Meow Meow’; 
‘Bubbles’; 
Mephedrone; 
Methylone; 
MPDV; α-PVP, 
and many 
others; 
• Euphoria, mood enhancement; openness; 
empathy; mental clarity; elation; increased 
libido; 
• Restlessness; anxiety; hallucinatory 
experiences; psychosis;  
• Tachycardia; hypertension; abdominal pain; 
chills; flushing; sweating; hyperthermia; 
renal failure; rhabdomyolysis; seizures; 
serotonin syndrome; 
• chronic use:  paranoid ideation and mood 
disturbances;  
Monoamine transporter 
substrates with DAT-selective 
profiles  
Non-substrate transporter 
inhibitors 
Aminorex 
derivatives 
Para-methyl derivative of 
4-methylaminorex and 
analogues 
DA/NA releasing action and 
SERT inhibition 
‘Serotoni’; 
’4,4’-
dimethylaminore
x/DMAR 
• Elation; increased alertness; anxiety; 
agitation; 
• Increased body temperature; 
cardiorespiratory issues; 
Methylphen
idate-like 
NPS 
Ethyl-homologue of 
methylphenidate 
Potent DAT and NERT inhibition ‘El Burst’;’El 
Blanco’; 
Ethylphenidate; 
 
• Euphoria; elation; increased arousal; 
improved concentration, sociability, and 
sexual drive; 
• Muscle tension; palpitations; sweating; 
appetite loss; anxiety and restlessness;  
• Insomnia; paranoia; hallucinations; 
• Bizarre and violent behaviour; suicidality; 
psychosis; relapse of psychotic disorder 
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Novel 
Amphetami
ne 
type 
stimulants 
Analogues of 
amphetamine and 
methylamphetamine 
Variable levels of SERT, 
NET and DAT inhibitory 
potencies 
PMA;PMMA; 4-
MTA; DMA; MPA; 
diclofensine 
• Euphoria; increased energy and sexual 
drive; improved sociability; colour and 
sound amplification;  
• Increased alertness and anxiety levels; loss 
of appetite; 
• Tachycardia; increased body temperature 
Synthetic 
cocaine 
substitutes  
Benzoic acid esters DAT inhibition Dimethocaine 
 
•   Increased concentration and attention;    
   talkativeness; 
• Tachycardia; diaphoresis; muscle twitching; 
nausea; vomiting; peripheral vasoconstriction 
p-FBT • Hypertension; tachycardia;  
• Anxiety; temporary psychosis; 
3-phenyltropane 
analogues 
SERT, NET and DAT inhibitory 
properties 
RTI-111; RTI-
121; RTI-126 
• Euphoria; talkativeness;  
• Increased alertness; anxiety; paranoid   
ideation; 
• Insomnia; crash-like symptoms  
Amino-
indanes 
 
 
Aminoindane analogues Serotonin release and SERT 
inhibition 
MDAI; 5-IAI; 
ETAI; 
• Euphoria; elation; mood enhancement; 
openness, empathy; mental clarity; 
increased energy and libido; 
• Eye and skin irritation; gastrointestinal, and 
respiratory disturbances;  
• Serotonin syndrome 
DAT: dopamine transporter; SERT: serotonin transporter; NERT: norepinephrine transporter 
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Hallucinogenic NPS 
Class Structure Action Gergal/colloqui
al names 
Psychoactive effects and 
medical/psychopathological 
consequences 
Synthetic 
cannabimi-
metics  
 
 
 
 
Large class of compounds 
with different chemical 
structures 
CB1, CB2 receptor full 
agonism;5-HT, nicotinic, 
glycine, and NMDA receptors’ 
interaction 
‘Spice’; ‘K2’; 
‘Bonzai’; 
‘clockwork 
orange’; 
‘psyclone’; 
JWH-018; HU-
210; XLR-11;5F-
AKB48; PB-22;  
ADB-PINACA; 
MAB-CHMINACA; 
and many others 
 
• Visual and auditory hallucinations; paranoid 
ideation; 
• Anxiety/panic attacks; agitation; 
behavioural dyscontrol; excited delirium; 
• Suicidal ideation;  manic-like symptoms; 
relapse of bipolar disorders;  
• Temporary psychosis; relapse of psychotic 
disorders; persisting psychotic 
disorders/‘Spiceophrenia’  
• Tachycardia; hypertension; 
dyspnoea/tachypnoea; mydriasis; nausea; 
vomiting; hypokalaemia;  
• Acute kidney injuries; myocardial infarction; 
liver failure; 
• Nystagmus; seizures; encephalopahy; 
stroke; 
• Rhabdomyolysis; hyperthermia; serotonin 
syndrome possible 
 
Psychedelic 
phenethylam
ines   
 
 
 
 
 
 
 
 
 
 
2C-B difuran analogue 5-HT2A agonism; 5-HT2B and 
5-HT2C affinity  
‘Bromodragonfly’ • Long standing hallucinations; paranoid 
ideation; mood elevation; confusion; 
anxiety; flashbacks; 
• Convulsions; respiratory issues; liver failure; 
kidney failure; vasoconstriction; 
2C-B derivatives 5-HT2A affinity; D2 low 
affinity;  monoamine 
transporters’ low inhibitory 
activity levels 
'2C-series’; 
‘Nexus’; 
2C-D; 2C-E; 2C-
N; 2C-H; and 
others; 
 
 
• Hallucinations; dysphoria; severe agitation; 
• Mydriasis; seizures; headache; apnoea 
 
 
 
 
‘N-bomb’; • Visual, auditory, olfactory, and tactile 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
ert
fo
rd
sh
ire
], 
[Jo
hn
 C
or
ke
ry
] a
t 0
2:4
0 1
8 M
arc
h 2
01
6 
 N-benzyl substituted 
phenethylamines 
5-HT2A and 5-HT2C  full 
agonism; α1A , α2A and H1 
high binding affinity; D2 and 
D3 low-affinity  
25B-NBOMe;  
25C-NBOMe;  
25I-NBOMe 
  
 
 
  
 
 
 
hallucinations; 
• Euphoria; increased sociability; empathy; 
• Depersonalisation; dissociation; 
derealization; 
• Panic; severe agitation; insomnia; 
aggressiveness; 
• Nausea; vomiting; headache; seizures; 
muscle rigidity; rhabdomyolysis; tremors; 
• Renal failure; cardiopulmonary arrest; 
MDA benzofuran 
analogues 
5-HT2A and 5-HT2B agonism; 
DAT, α2c affinity; SERT 
inhibition 
‘BenzoFury’; 
5-APB; 6-APB; 
and others  
 
 
• Euphoria; elation; entactogenic properties; 
hallucinations;  
• Agitation; panic attacks; insomnia; 
• Severe paranoia; psychosis; 
• Unpleasant come-down; depression; 
• Nausea; hot flushes; headache; jaw 
clenching; 
• Serotonin syndrome possible 
Tryptamines 
 
Tryptamine derivatives 
 
5-HT1A,,5-HT2A,5-HT2C  
agonism; VMAT2, σ-1, SERT, 
TAR interactions 
4-HO-DALT;  
5-MeO-DMT;  
5-MeO-DIPT;  
5-Meo-DALT; 
and others 
• Visual hallucinations common; auditory 
hallucinations possible;  
• Intensification of colours; distortion of body 
image; depersonalization; 
• Euphoria; marked mood lability; 
relaxation;entactogenic properties; 
• Anxiety; panic disorder; agitation; 
restlessness; paranoia; excited delirium; 
• Tachyarrhythmia; hyperpyrexia; 
Hypertension;  
• Nausea; vomiting; muscle tension; 
• Serotonin syndrome possible 
Ergolines LSD-related compounds 5-HT2A agonism and/or other 
5-HT2 receptors 
agonism/interactions 
LSZ; 1-P-LSD; 
ETH-LAD; PRO-
LAD; AL-LAD; 
 
 
• Hallucinations; time distortion; body image 
alterations; 
• Bad trips; flashbacks; 
• Headache; nausea; mydriasis; tachycardia; 
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DAT: dopamine transporter; SERT: serotonin transporter; NERT: norepinephrine transporter; VMAT2: vesicular monoamine transporter 2; 
TAR: traceamine-associated receptors; 
 
 
 
 hyperpyrexia; hypertension 
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